Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin.
Animals
Camelus
Cell Survival
/ drug effects
Chickens
Diphtheria Toxin
/ administration & dosage
Dose-Response Relationship, Drug
HEK293 Cells
Human Umbilical Vein Endothelial Cells
/ drug effects
Humans
Immunotoxins
/ administration & dosage
MCF-7 Cells
Male
Neovascularization, Pathologic
/ immunology
Neuropilin-1
/ antagonists & inhibitors
Single-Domain Antibodies
/ administration & dosage
Immunotoxin
NRP-1
VHH
diphtheria toxin
targeted cancer therapy
Journal
Immunopharmacology and immunotoxicology
ISSN: 1532-2513
Titre abrégé: Immunopharmacol Immunotoxicol
Pays: England
ID NLM: 8800150
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
pubmed:
5
3
2021
medline:
21
10
2021
entrez:
4
3
2021
Statut:
ppublish
Résumé
Neuropilin-1 (NRP-1) regulates a range of physiological and pathological processes, including angiogenesis. Targeting of NRP1 is considered a significant approach in cancer therapy. In the present study, a novel antiNRP1 immunotoxin (αNRP1 IT) was developed by genetic fusion of a single domain (VHH) anti-NRP-1 antibody fragment to a truncated diphtheria toxin. The αNRP1 IT was expressed into bacterial cells as an inclusion body (IB). Expression of αNRP1 IT was confirmed by SDS-PAGE and western blotting. Recombinant αNRP1 IT was purified using nickel affinity chromatography. Toxicity and antiangiogenesis effect of αNRP1 IT was investigated both
Identifiants
pubmed: 33657977
doi: 10.1080/08923973.2021.1888114
doi:
Substances chimiques
Diphtheria Toxin
0
Immunotoxins
0
NRP1 protein, human
0
Single-Domain Antibodies
0
Neuropilin-1
144713-63-3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM